Chicagoland Peptides

Chicagoland Peptides products are Research Use Only ("RUO") and are intended solely for basic research, pharmaceutical research, laboratory experimentation, or the development of new tests — not for diagnosing, treating, curing, or preventing any disease or condition in any patient. These statements have not been evaluated by the U.S. Food and Drug Administration.

Learn

Start here

Start Here

What laboratory-device literature reports about research-use-only labeling, certificates of analysis, and HPLC purity versus identity testing.

Last reviewed: September 15, 2026

Storage & handling

Storage & Handling
What published stability literature reports about lyophilised versus liquid peptides, temperature, light, and freeze–thaw, as studied in vitro.
Last reviewed: September 15, 2026

BPC-157

BPC-157
What published studies reported for BPC-157, labelled by model: in vitro, animal, or human tissue.
Last reviewed: September 15, 2026

Semaglutide

Semaglutide and the GLP-1 Receptor: What Binding and Receptor-Engagement Assays Report
A research-library survey of published structural, radioligand competition, cell-based signalling, and albumin-binding assay work in which semaglutide was characterised or used as a comparator at the GLP-1 receptor, with the model system (in vitro, animal, or human) stated for each finding.
Last reviewed: September 16, 2026

Tirzepatide

Tirzepatide Pharmacokinetics in Animal Models: What the Published Literature Reports
A research-framed summary of published findings on tirzepatide disposition in rats, including a validated LC-MS/MS bioanalytical method, reported terminal half-lives after intravenous and subcutaneous administration, and estimated subcutaneous bioavailability, alongside a scoping review mapping preclinical and clinical evidence for this dual GIP/GLP-1 receptor agonist.
Last reviewed: September 16, 2026